Isolation of cancer stem cells from three human glioblastoma cell lines: characterization of two selected clones

PLoS One. 2014 Aug 14;9(8):e105166. doi: 10.1371/journal.pone.0105166. eCollection 2014.

Abstract

Cancer stem cells (CSC) were isolated via a non-adherent neurosphere assay from three glioma cell lines: LI, U87, and U373. Using a clonal assay, two clones (D2 and F11) were selected from spheres derived from LI cells and were characterized for the: expression of stem cell markers (CD133, Nestin, Musashi-1 and Sox2); proliferation; differentiation capability (determined by the expression of GalC, βIII-Tubulin and GFAP); Ca(2+) signaling and tumorigenicity in nude mice. Both D2 and F11 clones expressed higher levels of all stem cell markers with respect to the parental cell line. Clones grew more slowly than LI cells with a two-fold increase in duplication time. Markers of differentiation (βIII-Tubulin and GFAP) were expressed at high levels in both LI cells and in neurospheres. The expression of Nestin, Sox2, and βIII-Tubulin was down-regulated in D2 and F11 when cultured in serum-containing medium, whereas Musashi-1 was increased. In this condition, duplication time of D2 and F11 increased without reaching that of LI cells. D2, F11 and parental cells did not express voltage-dependent Ca(2+)-channels but they exhibited increased intracellular Ca(2+) levels in response to ATP. These Ca(2+) signals were larger in LI cells and in spheres cultured in serum-containing medium, while they were smaller in serum-free medium. The ATP treatment did not affect cell proliferation. Both D2 and F11 induced the appearance of tumors when ortotopically injected in athymic nude mice at a density 50-fold lower than that of LI cells. All these data indicate that both clones have characteristics of CSC and share the same stemness properties. The findings regarding the expression of differentiation markers and Ca(2+)-channels show that both clones are unable to reach the terminal differentiation. Both D2 and F11 might represent a good model to improve the knowledge on CSC in glioblastoma and to identify new therapeutic approaches.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers, Tumor / metabolism
  • Blotting, Western
  • Brain Neoplasms / pathology*
  • Cell Differentiation
  • Cell Line, Tumor
  • Clone Cells*
  • Culture Media
  • Flow Cytometry
  • Glioblastoma / pathology*
  • Humans
  • Mice
  • Mice, Nude
  • Neoplastic Stem Cells / pathology*

Substances

  • Biomarkers, Tumor
  • Culture Media

Grants and funding

This work has received a French government support granted to the CominLabs excellence laboratory and managed by the National Research Agency in the “Investing for the Future” program under reference ANR-10-LABX-07-01. It was also supported by the Rennes University Hospital (COREC Project named conneXion, 2012–14). We also thank the European Research Council for the ERC-2011-ADG - Grant Agreement N° 290901 – Acronym “NEUCOD”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.